Strategic infection prevention after genetically modified hematopoietic stem cell therapies: recommendations from the International Society for Cell & Gene Therapy Stem Cell Engineering Committee

IF 3.7 3区医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Cytotherapy Pub Date : 2024-07-01 DOI:10.1016/j.jcyt.2024.02.005

Tami D. John , Gabriela Maron , Allistair Abraham , Alice Bertaina , Senthil Velan Bhoopalan , Alan Bidgoli , Carmem Bonfim , Zane Coleman , Amy DeZern , Jingjing Li , Chrystal Louis , Joseph Oved , Mara Pavel-Dinu , Duncan Purtill , Annalisa Ruggeri , Athena Russell , Robert Wynn , Jaap Jan Boelens , Susan Prockop , Akshay Sharma

{"title":"Strategic infection prevention after genetically modified hematopoietic stem cell therapies: recommendations from the International Society for Cell & Gene Therapy Stem Cell Engineering Committee","authors":"Tami D. John , Gabriela Maron , Allistair Abraham , Alice Bertaina , Senthil Velan Bhoopalan , Alan Bidgoli , Carmem Bonfim , Zane Coleman , Amy DeZern , Jingjing Li , Chrystal Louis , Joseph Oved , Mara Pavel-Dinu , Duncan Purtill , Annalisa Ruggeri , Athena Russell , Robert Wynn , Jaap Jan Boelens , Susan Prockop , Akshay Sharma","doi":"10.1016/j.jcyt.2024.02.005","DOIUrl":null,"url":null,"abstract":"<div><p>There is lack of guidance for immune monitoring and infection prevention after administration of <em>ex vivo</em> genetically modified hematopoietic stem cell therapies (GMHSCT). We reviewed current infection prevention practices as reported by providers experienced with GMHSCTs across North America and Europe, and assessed potential immunologic compromise associated with the therapeutic process of GMHSCTs described to date. Based on these assessments, and with consensus from members of the International Society for Cell & Gene Therapy (ISCT) Stem Cell Engineering Committee, we propose risk-adapted recommendations for immune monitoring, infection surveillance and prophylaxis, and revaccination after receipt of GMHSCTs. Disease-specific and GMHSCT-specific considerations should guide decision making for each therapy.</p></div>","PeriodicalId":50597,"journal":{"name":"Cytotherapy","volume":null,"pages":null},"PeriodicalIF":3.7000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1465324924000525/pdfft?md5=da9fe7fde8440b290f7637aa56a8a953&pid=1-s2.0-S1465324924000525-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cytotherapy","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1465324924000525","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

There is lack of guidance for immune monitoring and infection prevention after administration of ex vivo genetically modified hematopoietic stem cell therapies (GMHSCT). We reviewed current infection prevention practices as reported by providers experienced with GMHSCTs across North America and Europe, and assessed potential immunologic compromise associated with the therapeutic process of GMHSCTs described to date. Based on these assessments, and with consensus from members of the International Society for Cell & Gene Therapy (ISCT) Stem Cell Engineering Committee, we propose risk-adapted recommendations for immune monitoring, infection surveillance and prophylaxis, and revaccination after receipt of GMHSCTs. Disease-specific and GMHSCT-specific considerations should guide decision making for each therapy.

查看原文本刊更多论文

转基因造血干细胞疗法后的感染预防策略：国际细胞与基因治疗学会干细胞工程委员会的建议

体外基因修饰造血干细胞疗法（GMHSCT）用药后的免疫监测和感染预防缺乏指导。我们回顾了北美和欧洲具有基因改造造血干细胞移植经验的医疗机构所报告的当前感染预防方法，并评估了迄今为止所描述的与基因改造造血干细胞移植治疗过程相关的潜在免疫损伤。基于这些评估，并在国际细胞与印记基因治疗学会（ISCT）干细胞工程委员会成员的共识下，我们提出了接受基因改造人造血干细胞移植后进行免疫监测、感染监控和预防以及再接种的风险调整建议。针对特定疾病和基因改造造血干细胞移植的考虑因素应指导每种疗法的决策。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cytotherapy 医学-生物工程与应用微生物

CiteScore

6.30

自引率

4.40%

发文量

683

审稿时长

49 days

期刊介绍： The journal brings readers the latest developments in the fast moving field of cellular therapy in man. This includes cell therapy for cancer, immune disorders, inherited diseases, tissue repair and regenerative medicine. The journal covers the science, translational development and treatment with variety of cell types including hematopoietic stem cells, immune cells (dendritic cells, NK, cells, T cells, antigen presenting cells) mesenchymal stromal cells, adipose cells, nerve, muscle, vascular and endothelial cells, and induced pluripotential stem cells. We also welcome manuscripts on subcellular derivatives such as exosomes. A specific focus is on translational research that brings cell therapy to the clinic. Cytotherapy publishes original papers, reviews, position papers editorials, commentaries and letters to the editor. We welcome "Protocols in Cytotherapy" bringing standard operating procedure for production specific cell types for clinical use within the reach of the readership.